AU2002365622A1 - Novel glucagon antagonists - Google Patents

Novel glucagon antagonists

Info

Publication number: AU2002365622A1
Authority: AU; Australia
Prior art keywords: glucagon antagonists; novel glucagon; novel; antagonists; glucagon
Prior art date: 2001-12-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002365622A

Other languages

English (en)

Inventor

Inge Thoger Christensen

Anker Steen Jorgensen

Janos Tibor Kodra

Jesper Lau

Peter Madsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-03

Filing date

2002-11-28

Publication date

2003-06-17

2002-11-28 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

2003-06-17 Publication of AU2002365622A1 publication Critical patent/AU2002365622A1/en

Status Abandoned legal-status Critical Current

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AU2002365622A 2001-12-03 2002-11-28 Novel glucagon antagonists Abandoned AU2002365622A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200101789		2001-12-03
DKPA200101789		2001-12-03
DKPA200201117		2002-07-18
DKPA200201117		2002-07-18
PCT/DK2002/000800 WO2003048109A1 (fr)	2001-12-03	2002-11-28	Nouveaux antagonistes de glucagon

Publications (1)

Publication Number	Publication Date
AU2002365622A1 true AU2002365622A1 (en)	2003-06-17

Family

ID=26069105

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002365622A Abandoned AU2002365622A1 (en)	2001-12-03	2002-11-28	Novel glucagon antagonists

Country Status (4)

Country	Link
EP (1)	EP1463715A1 (fr)
JP (1)	JP2005511683A (fr)
AU (1)	AU2002365622A1 (fr)
WO (1)	WO2003048109A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7572922B2 (en)	2003-01-27	2009-08-11	Merck & Co., Inc.	Substituted pyrazoles, compositions containing such compounds and methods of use
EP1758859B1 (fr) *	2004-05-28	2013-07-17	Eli Lilly And Company	Antagonistes vis-a-vis des recepteurs du glucagon, elaboration et utilisations therapeutiques
SI1758853T1 (sl) *	2004-06-14	2010-05-31	Lilly Co Eli	Antagonisti glukagonskega receptorja priprava inuporaba v terapiji
US7622491B2 (en) *	2004-08-13	2009-11-24	Metabolex Inc.	Modulators of PPAR and methods of their preparation
PT1856090E (pt) *	2005-02-11	2009-11-18	Lilly Co Eli	Derivados de tiofeno substituído como antagonistas do receptor de glucagona, preparação e usos terapêuticos
EP1863755A1 (fr)	2005-03-21	2007-12-12	Merck & Co., Inc.	Derives d'aryle et d'heteroaryle substitues
JP2008534593A (ja)	2005-03-30	2008-08-28	メルクエンドカムパニーインコーポレーテッド	グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法
US20090239944A1 (en) *	2005-06-24	2009-09-24	D Orazio Daniel	Novel Use of Organic Compounds
CN101300232A (zh)	2005-07-26	2008-11-05	默克公司	合成取代的吡唑的方法
TW200745031A (en)	2005-10-13	2007-12-16	Merck & Co Inc	Acyl indoles, compositions containing such compounds and methods of use
BRPI0618349A2 (pt)	2005-11-17	2011-08-23	Lilly Co Eli	composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e , uso de um composto ou um sal do mesmo
CN101312940B (zh)	2005-11-17	2012-11-14	伊莱利利公司	胰高血糖素受体拮抗剂、制备和治疗用途
DK1951659T3 (da)	2005-11-18	2010-10-11	Lilly Co Eli	Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
WO2007120270A2 (fr)	2005-11-22	2007-10-25	Eli Lilly And Company	Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
BRPI0618745A2 (pt) *	2005-11-23	2011-09-13	Lilly Co Eli	composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou um sal do mesmo
WO2007111864A2 (fr)	2006-03-23	2007-10-04	Merck & Co., Inc.	Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
JP2009537525A (ja)	2006-05-16	2009-10-29	メルクエンドカムパニーインコーポレーテッド	グルカゴン受容体アンタゴニスト化合物、このような化合物を含む組成物及び使用方法
TW200821284A (en)	2006-10-03	2008-05-16	Merck & Co Inc	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20170085615A (ko)	2007-02-09	2017-07-24	메타베이시스 테라퓨틱스, 인크.	글루카곤 수용체의 길항제
EP2210876B1 (fr) *	2007-11-01	2015-05-20	Takeda Pharmaceutical Company Limited	Composé hétérocyclique en tant qu'antagoniste de glucagon
CN102015641B (zh) *	2008-03-05	2014-01-01	武田药品工业株式会社	杂环化合物
US8623818B2 (en)	2008-05-16	2014-01-07	Merck Sharp & Dohme Corp.	Glucagon receptor antagonists, compositions, and methods for their use
CA2966273C (fr)	2008-08-13	2019-08-27	Metabasis Therapeutics, Inc.	Antagonistes de glucagon
CN101768149B (zh) *	2008-12-30	2013-10-30	成都地奥制药集团有限公司	一类β-氨基酮(醇)衍生物及其用途
WO2010088061A1 (fr)	2009-01-28	2010-08-05	Merck Sharp & Dohme Corp.	Composés antagonistes du récepteur du glucagon, compositions contenant ces composés et leurs procédés d'utilisation
PE20100443A1 (es) *	2009-02-06	2010-06-25	Takeda Pharmaceutical	Derivados del acido fenil-carbonil-amino-propanoico como antagonistas del glucagon
WO2011027849A1 (fr) *	2009-09-04	2011-03-10	武田薬品工業株式会社	Composé hétérocyclique
CA2822017C (fr)	2010-12-23	2015-04-07	Pfizer Inc.	Modulateurs du recepteur du glucagon
CN103370306B (zh)	2011-02-08	2015-12-02	辉瑞大药厂	胰高血糖素受体调节剂
WO2012162409A1 (fr) *	2011-05-23	2012-11-29	Janssen Pharmaceutica Nv	Dérivés de biphényle utiles en tant qu'antagonistes de récepteurs du glucagon
AU2012258771A1 (en) *	2011-05-23	2013-11-14	Janssen Pharmaceutica Nv	Picolinamido - propanoic acid derivatives useful as glucagon receptor antagonists
WO2013014569A1 (fr)	2011-07-22	2013-01-31	Pfizer Inc.	Modulateurs des récepteurs de quinolinylglucagon
WO2013138753A1 (fr)	2012-03-16	2013-09-19	Fox Chase Chemical Diversity Center, Inc.	Promédicaments de riluzole et leur méthode d'utilisation
BR112015020391B1 (pt)	2013-02-22	2022-07-26	Samumed, Llc	Gama-dicetonas como ativadoras da via de sinalização de wnt/beta-catenina
US9649294B2 (en)	2013-11-04	2017-05-16	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10076504B2 (en)	2014-06-12	2018-09-18	Ligand Pharmaceuticals, Inc.	Glucagon antagonists
CN107205970A (zh)	2014-11-05	2017-09-26	弗莱塞斯生物科学公司	免疫调节剂
WO2017215586A1 (fr) *	2016-06-14	2017-12-21	浙江海正药业股份有限公司	Dérivés d'amide, leur procédé de préparation et leur utilisation en médecine
AU2018212616A1 (en) *	2017-01-27	2019-08-29	Genfit	RORgamma modulators and uses thereof
JP2021513564A (ja)	2018-02-13	2021-05-27	リガンド・ファーマシューティカルズ・インコーポレイテッド	グルカゴン受容体拮抗薬
CN110357813A (zh) *	2018-04-09	2019-10-22	信达生物制药(苏州)有限公司	一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613942B1 (en) *	1997-07-01	2003-09-02	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
AU2001265834A1 (en) *	2000-06-23	2002-01-08	Novo Nordisk A/S	Glucagon antagonists/inverse agonists

2002
- 2002-11-28 WO PCT/DK2002/000800 patent/WO2003048109A1/fr not_active Ceased
- 2002-11-28 AU AU2002365622A patent/AU2002365622A1/en not_active Abandoned
- 2002-11-28 JP JP2003549302A patent/JP2005511683A/ja not_active Withdrawn
- 2002-11-28 EP EP02804158A patent/EP1463715A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
JP2005511683A (ja)	2005-04-28
EP1463715A1 (fr)	2004-10-06
WO2003048109A1 (fr)	2003-06-12

Publication	Publication Date	Title
AU2002365622A1 (en)	2003-06-17	Novel glucagon antagonists
AU2001255798A1 (en)	2001-11-12	Glucagon antagonists
AU2002341834A1 (en)	2003-04-07	Antagonists
AU2002360508A1 (en)	2003-06-23	Substituted hydroxyethylamines
SI1671949T1 (sl)	2008-10-31	Substituirani pridinilamini
AU2002367404A1 (en)	2003-07-24	Redox-switchable materials
AU2002367336A1 (en)	2003-07-24	Stairway
AU2003291959A1 (en)	2004-07-14	Novel glucagon antagonists
AU2002359320A1 (en)	2003-05-12	Novel anit-infectives
AU2002365655A1 (en)	2003-06-17	5-ht7 receptor antagonists
AU2002251024A1 (en)	2003-03-20	Substituted fluoroalcoxyphenylsulfonylurea
PL362643A1 (en)	2004-11-02	Substituted fluoroalcoxyphenylsulfonylurea
AU2002321215A1 (en)	2003-05-22	Substituted 4-aminocyclohexanols
PL368050A1 (en)	2005-03-21	Substituted 4-aminocyclohexanols
AU2002241899A1 (en)	2002-09-12	Tip39 polypeptides
AU2002247861A1 (en)	2002-10-28	Modified calcitonin
AU2002346030A1 (en)	2003-01-21	Novel receptors
WO2002077001A9 (fr)	2013-10-31	Nouveaux recepteurs
PL364601A1 (en)	2004-12-13	Substituted benzo-nitro-heterocycles
AUPR918701A0 (en)	2001-12-20	Tile
AU2002346278A1 (en)	2003-02-17	Tile
AU2002360933A1 (en)	2003-05-19	Antagonists for alpha4-integrins
AU2002311774A1 (en)	2002-10-08	Novel receptors
AU2002310084A1 (en)	2002-12-03	Ccr4 antagonists
AU2002363642A1 (en)	2003-05-26	Nk1 antagonists

Legal Events

Date	Code	Title	Description
2004-08-19	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase